IRICoR is pleased to share news from our partner, Domain Therapeutics.

Domain Therapeutics grants Bristol-Myers Squibb non-exclusive license for G protein-coupled receptor bioSens-All™ technology

Technology provides access to new generation of sensitive biosensors to enhance drug discovery

Strasbourg, France, February 27, 2018 – Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target transmembrane receptors, today announces the signing of a licensing agreement for its bioSens-All™ technology with Bristol-Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb will make an upfront payment for access to the technology, with additional payments on identification of development candidates. Further financial elements of the license were not disclosed. To read the press release click here.